艾弗梅克丁在菌形虫 (Chlamydia trachomatis) 的传播中可能起到缓解作用,这种作用是由Muska sorbens所造成的
Richard Selby1, Anita Jeyam1, Andrew Tate1
1Sightsavers international, 35 Perrymount Road, Haywards Heath, West Sussex, United Kingdom.
PLoS neglected tropical diseases
|October 26, 2023
概括
伊弗梅克丁 (IVM) 可能会改善气管瘤的控制,当与阿兹罗密辛 (AZM) 联合时,大规模药物管理 (MDA). 这一策略可以通过准菌来增强SAFE方法,菌是气管瘤的载体.
科学领域:
- 公共卫生 公共卫生
- 传染病流行病学 传染病流行病学
- 矢量控制控制器 矢量控制器
背景情况:
- 气管瘤是导致失明的主要传染病,与卫生条件和卫生条件不佳有关.
- 手术,抗生素,面部清洁和环境改善 (SAFE) 策略,包括阿齐思罗米辛 (AZM) 大量药物管理 (MDA),是控制气管瘤的关键.
- 在露天排便后的便中繁殖的Musca sorbens,被怀疑是气管瘤的载体.
研究的目的:
- 调查已知可以抑制昆虫在便中繁殖的ivermectin (IVM) 是否可以作为对M. sorbens的载体控制工具.
- 评估IVM和AZMMMDA与埃塞俄比亚持续或复发性气管瘤区域的气管瘤控制之间的协会.
主要方法:
- 追溯分析埃塞俄比亚的大规模药物管理 (MDA) 计划中瘤,瘤瘤和淋巴状腺瘤的现有数据.
- 对持续性或复发性气管瘤的评估单位 (EU) 的检查.
- 欧盟接受AZM MDA单独治疗的患者和接受AZM和IVM MDA治疗的患者的气管瘤控制结果的比较.
主要成果:
- 观察到一种关联,表明在欧盟接受IVM和AZM MDA的患者中,与仅接受AZM MDA的患者相比,有改善的气管瘤控制.
- 在患有持续性或复发性气管瘤的地区观察到这种效应.
- 这些发现支持IVM作为SAFE战略的辅助工具的潜力.
结论:
- 与阿齐思罗米大规模药物管理同时使用的艾弗梅克丁可能会增强气管瘤的控制,特别是在持续或复发的病例中.
- 伊弗梅克显示出作为对Musca sorbens的载体控制工具的潜力,支持SAFE战略的环境改善组成部分.
- 需要进一步进行受控的实验室和实地研究,以验证艾弗梅克丁对M. sorbens繁殖的影响以及其对气管瘤控制的有效性.
相关概念视频
01:29Bacterial Phylum Chlamydiae
20
The phylum Chlamydiae or Chlamydiota is composed of a single order, Chlamydiales. This phylum consists entirely of obligate intracellular parasites that infect eukaryotic hosts. While human pathogens within this group have been studied extensively, the phylum encompasses many species capable of interacting with various eukaryotic organisms. Members of Chlamydiae are typically small cocci, approximately 0.5 μm in diameter, and exhibit a distinctive developmental cycle. As is characteristic...
20
01:26Sexually Transmitted Infections
328
Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
328
01:26Cholinergic Antagonists: Therapeutic Uses
758
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
758
01:28Cholinergic Antagonists: Pharmacological Actions
1.1K
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics:
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
1.1K